UNSPSC 51182031: Mesterolone

This classification denotes a therapeutic androgen with the molecular formula C20H32O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0SRQ75X9I9, chemically known as 5alpha-androstan-3-one, 17beta-hydroxy-1alpha-methyl- but generally known as mesterolone, which bears US NIH Compound Identifier 15020. European Medicines Agency schedules Mesterolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08790MIG.

UNSPSC 51182031 Mesterolone is a Commodity code representing a single pharmaceutical product line. State and local procurement activity under this code centers on the acquisition of generic and branded mesterolone through multistate cooperative purchasing frameworks that aggregate demand across health and human services agencies, correctional facilities, and other state and local government healthcare operations. The issuing bodies soliciting under this code are primarily state departments of administration and multistate purchasing alliances that serve state agencies and participating local government entities, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) emerging as a significant repeat buyer establishing centralized pharmaceutical supply agreements that distribute through authorized wholesalers to multiple participating jurisdictions.

MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026, due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products including mesterolone. The procurement requires vendors to maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and submit pricing in formats including flat price, net price (NF30, NF60, NF90), or WAC-minus structures. Evaluation emphasizes price competitiveness (75 percent weight), with secondary criteria including fixed pricing (10 percent), EDI capability (5 percent), administrative fee compliance (5 percent), and data format requirements (5 percent). The contract term is two years for new vendors, with optional extensions at MMCAP's discretion, effective July 1, 2026. Vendors must carry commercial general liability insurance of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, with all products required to comply with FDA standards and maintain expiration dates of at least one year from manufacture.